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Abstract We have investigated membrane interactions and
perturbations induced by NH2-DKWASLWNWFNITNWL-
WYIK-COOH (HIVc), representing the membrane interface-
partitioning region that precedes the transmembrane anchor of
the human immunodeficiency virus type-1 gp41 fusion protein.
The HIVc peptide bound with high affinity to electrically neutral
vesicles composed of dioleoylphosphatidylcholine, dioleoylpho-
sphatidylethanolamine and cholesterol (molar ratio, 1:1:1), and
induced vesicle leakage and lipid mixing. Infrared spectra
suggest that these effects were promoted by membrane-
associated peptides adopting an K-helical conformation. A
sequence representing a defective gp41 phenotype unable to
mediate both cell^cell fusion and virus entry, was equally unable
to induce vesicle fusion, and adopted a non-helical conformation
in the membrane. We conclude that membrane perturbation and
adoption of the K-helical conformation by this gp41 region might
be functionally meaningful. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The gp120/41 envelope protein is a type 1 integral glyco-
protein responsible for the binding and subsequent fusion of
HIV-1 to its host cell membrane [1,2]. Upon binding-induced
activation, the fusion peptide at the N-terminus of the gp41
transmembrane subunit becomes inserted into the target mem-
brane, thus making gp41 an integral component of two mem-
branes, i.e. virus and target cell [1^3]. Subsequent structural
alterations have been postulated to induce apposition of the
target cell and viral membranes [4,5]. Previous work seems to
indicate that within the fusion loci, apposed target membranes
might be distorted by the action of the fusion peptides [6,7].
We show here that the sequence preceding the transmembrane
anchor of gp41 may be able to perturb membranes as well.
This Trp-rich sequence, spanning residues 664^683, shows a
potential high tendency to partition into the membrane inter-
face as revealed by the interfacial hydrophobicity scale devel-
oped by Wimley and White [8^10]. This makes this sequence a
suitable candidate to be a membrane-perturbing agent. The
high degree of residue conservation and recent mutational
analysis highlight the crucial role of this segment in the fusion
activity of gp41 [11]. Functional characterization in cells ex-
pressing the human immunode¢ciency virus type-1 (HIV-1)
env mutant products reveals that the pre-transmembrane do-
main might actually be involved in the opening of the fusion
aqueous pore [12].
Using unilamellar vesicles made of an equimolar mixture of
dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidyl-
ethanolamine (DOPE) and cholesterol (CHOL) as targets we
have experimentally demonstrated that a 20 amino acid pep-
tide, corresponding to the region adjacent to the transmem-
brane segment of gp41, shows a high tendency to partition
into membranes. In addition, when in contact with mem-
branes the same peptide can induce liposomal membrane de-
stabilization, i.e. permeabilization, and mixing of bilayer lip-
ids. These e¡ects are promoted by the membrane-associated
peptide folded as an K-helix. By contrast a peptide represent-
ing a non-functional gp41 as described by Salzwedel et al. [11]
was unable to induce lipid mixing in the same lipid system.
Moreover, this inactive peptide failed to adopt a helical con-
formation when associated with membranes. We conclude
that the sequence representing a functional gp41 may actually
distort membranes and induce the kind of bilayer structural
alterations that lead to membrane fusion. Our data are thus
consistent with this sequence playing a direct role during the
HIV-1 fusion cycle.
2. Materials and methods
DOPC, DOPE, CHOL and the £uorescent probes N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)phosphatidylethanolamine (N-NBD-PE) and N-
(lissamine rhodamine B sulfonyl)phosphatidylethanolamine (N-Rh-
PE) were purchased from Avanti Polar Lipids (Birmingham, AL,
USA). 8-Aminonaphthalene-1,3,6-trisulfonic acid sodium salt
(ANTS) and p-xylenebis(pyridinium)bromide (DPX) were from Mo-
lecular Probes (Junction City, OR, USA). N-Acetyl-L-tryptophana-
mide (NATA), octaethyleneglycol monododecyl ether (C12E8) and
Triton X-100 were obtained from Sigma (St. Louis, MO, USA). All
other reagents were of analytical grade. The sequences NH2-DKW-
ASLWNWFNITNWLWYIK-COOH (HIVc) (Fig. 1) and NH2-
DKAASLANAFNITNWLWYIK-COOH (HIVcÿmut) were synthe-
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sized as C-terminal carboxamides and puri¢ed (estimated homogene-
ity s 90%) by Quality Controlled Biochemicals, Inc. (Hopkinton,
MA, USA). Peptide stock solutions were prepared in dimethylsulfox-
ide (DMSO) (spectroscopy grade).
Large unilamellar vesicles (LUV) consisting of DOPC, DOPE and
CHOL (molar ratio, 1:1:1), were prepared according to the extrusion
method of Hope et al. [13] in 5 mM HEPES, 100 mM NaCl (pH 7.4).
Osmolalities were adjusted to 200 mOsm in a cryoscopic osmometer
(Osmomat 030, Gonotec, Berlin, Germany). Lipid concentrations of
liposome suspensions were determined by phosphate analysis [14]. The
average diameter of DOPC/DOPE/CHOL vesicles was of V130 nm
as estimated by quasielastic light scattering using a Malvern Zeta-
Sizer instrument.
Partitioning into DOPC/DOPE/CHOL LUV was estimated by
physically separating unbound and bound peptide. Unbound peptide
was removed from the mixtures by gel ¢ltration in a Sephadex G-75
column. Vesicles labeled with 0.1 mol% N-NBD-PE and N-Rho-PE (1
ml 1 mM total lipid) were incubated at 37‡C for 30 min with peptide
(0.01 mM) prior to gel ¢ltration. Chromatographed peptide^lipid
samples were subsequently solubilized with 2 mM C12E8 in order to
minimize the scattering contribution to Trp £uorescence. The Trp and
NBD signals allowed simultaneous quanti¢cation of co-eluting pep-
tide and lipid respectively.
Membrane lipid mixing was monitored using the resonance energy
transfer (RET) assay, described by Struck et al. [15]. The assay, based
on the dilution of N-NBD-PE and N-Rh-PE £uorescent probes as
lipid mixing is progressing, was adapted to our system as described
in [16]. Release of vesicular contents or leakage to the medium was
monitored by the ANTS/DPX assay [17]. The procedure is described
in detail in [15]. All these £uorescence measurements were conducted
in thermostatically controlled cuvettes (37‡C) using a Perkin-Elmer
LS50-B spectro£uorimeter. The medium in the cuvettes was continu-
ously stirred to allow the rapid mixing of peptide and vesicles.
The analysis of fusion kinetics of DOPC/DOPE/CHOL LUV con-
sidered aggregation, dissociation and fusion processes [18,19] and in-
volved the determination of the rate constants of those processes,
namely, aggregation C (M31 s31), dissociation D (s31) and fusion f
(s31) rate constants. The calculations were performed by introducing
certain modi¢cations into the program described in Nir et al. [20].
Infrared spectroscopy measurements were essentially conducted as
in [16]. Samples in the absence of vesicles consisted of peptides di-
rectly dissolved in D2O bu¡er. Before data acquisition these samples
were washed four times by centrifugation (peptide fractions were re-
covered from the pellets). Alternatively, in the presence of vesicles,
peptide^lipid complexes were obtained following a £otation protocol
(peptide bound to vesicles was recovered from £oating fractions) [24].
Infrared spectra were recorded in a Nicolet 550 spectrometer equipped
with a DTGS detector. Samples, containing V4 mg peptide/ml, were
placed between two CaF2 windows separated by 50 Wm spacers. 1000
scans (sample) and 1000 scans (reference) were taken for each spec-
trum, using a shuttle device. Spectra were transferred to a personal
computer where solvent subtraction and band position determinations
were performed.
3. Results and discussion
Fig. 1A displays the pre-transmembrane gp41 sequence
used in this work. The sequence consists of a stretch of un-
charged amino acids which is £anked by charged residues.
According to the interfacial hydrophobicity scale determined
by Wimley and White [8], Trp, Tyr and Phe residues show the
highest tendency to partitioning into the bilayer interface. The
pre-transmembrane sequence contains one Phe, one Tyr and
¢ve Trp residues. This fact explains that the overall interfacial
hydrophobicity of the sequence is very high. As shown by the
plot depicted in Fig. 1B, three prominent hydrophobic-at-in-
terface regions (main positive peaks above the zero midpoint
line) can be discerned within the gp41 subunit. The ‘FP’ re-
gion comprising residues 512^535 [3] corresponds to the fu-
sion peptide. The ‘pre-TM’ region comprises residues 664^683
and is located immediately preceding the transmembrane an-
chor. A third region, ‘LLP-3’, is a leucine zipper-like sequence
located within the cytoplasmic tail of the protein, spanning
residues 789^815 and representing the lentivirus lytic peptide-3
[21]. The ‘FP’ and the ‘LLP-3’ sequences are highly conserved
among HIV-1 isolates and have been experimentally shown to
interact with and perturb membranes [16,21,22]. Note that the
Wimley^White scale is based on di¡erent experimental data,
and aims at predicting a di¡erent property than the commonly
used hydropathy scales, so that in fact the former and the
latter scales lead to di¡erent results when applied to the
same peptide [10].
The above observations prompted us to analyze the ‘pre-
TM’ sequence as a putative membrane-interacting agent. To
that end, we made use of a synthetic peptide, HIVc, represent-
ing this region, and model membranes. As target model mem-
branes we selected suspensions of DOPC/DOPE/CHOL uni-
lamellar vesicles. The lipid composition was selected taking
into account that the HIV-1 envelope contains high levels of
cholesterol and, among phospholipids, phosphatidylcholine
and phosphatidylethanolamine are conspicuously represented
[23]. The suitability of these vesicles was previously demon-
strated in the characterization of the membrane interactions
and perturbations caused by the gp41 fusion peptide [24,25].
In addition, they provide a zwitterionic membrane interface
analogous to that used by Wimley and White to compose the
whole-residue interfacial hydrophobicity scale [8] (Fig. 1).
Trp £uorescence of the peptide incubated in the absence of
vesicles decreased with time, intensity becoming stabilized
Fig. 1. A: Schematic diagram of HIV-1 gp41 showing the location
of hydrophobic-at-interface regions and the pre-transmembrane se-
quence studied in this work. B: Hydropathy-at-interface plot for
HIV-1 gp41. The plotted stretch comprises residues 500^856 of
HIV-1 gp160 precursor (BH10 isolate, GenBank M15654). A win-
dow of 11 amino acids was used with the hydrophobicity scale at
membrane interfaces of Wimley and White [8]. In both panels, des-
ignated regions include: FP, fusion peptide; pre-TM, pre-transmem-
brane segment; TM, transmembrane domain; LLP-3, lentivirus lytic
peptide-3.
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after ca. 1 h (half-time ca. 15 min) at approximately 30% of
the initial value. Upon addition of vesicles, HIVc Trp emission
intensity at 342 nm increased almost instantaneously (data not
shown), then decreased, but at a lower rate than when incu-
bated in bu¡er alone. Since the £uorescence of the soluble Trp
analog NATA did not decrease under the same experimental
conditions, the intensity decrease in peptide samples was at-
tributed to changes occurring speci¢cally within the HIVc en-
vironment, most likely a self-quenching process arising from
peptide aggregation in solution due to its hydrophobic char-
acter. Taken together these results suggest that, even if bind-
ing to vesicles was much faster, a competing self-aggregation
process was decreasing the concentration of unbound mono-
mers in solution.
Consequently, the fraction of peptide monomers available
for membrane binding decreased with time. This outcome
prevented us from titrating the peptide in solution with in-
creasing amounts of lipid in order to estimate the dissociation
constant for the vesicle-bound/free peptide monomer equilib-
rium.
Therefore, we evaluated binding by physically separating
unbound peptide from peptide associated with vesicles by
means of gel ¢ltration. Under our experimental conditions
(see Section 2), for a peptide-to-lipid molar ratio of 1:100
we recovered 85^95% of the total amount of HIVc peptide
coeluting with vesicles. Assuming that the number of lipids
per HIVc binding site in the liposomes is comparable to that
estimated for fusion peptides of similar size [26], we would
obtain an apparent dissociation constant of V1 WM for the
peptide^vesicle binding site equilibrium. Given that the bind-
ing process is fast as compared to peptide self-aggregation (see
above) we may consider this estimate to be valid to describe
the initial partition of the peptide monomers into the DOPC/
DOPE/CHOL interface. This would correspond to a local and
transient equilibrium. A dissociation constant in the micro-
molar range under our conditions would indicate that the
peptide binds DOPC/DOPE/CHOL vesicles with high a⁄nity.
A high tendency to partition into vesicle membranes was
also re£ected by the low peptide doses required to destabilize
DOPC/DOPE/CHOL LUV (Fig. 2). The HIVc peptide readily
induces leakage of aqueous contents from the vesicles and
membrane fusion as evidenced by the occurrence of mem-
brane lipid mixing. Kinetic traces indicated higher initial leak-
age rates than lipid mixing rates at a ¢xed peptide-to-lipid
molar ratio (Fig. 2A). The extents (after 5 min) of membrane
mixing and leakage of contents with increasing amounts of
peptide are comparatively shown in Fig. 2B. At an added
peptide-to-lipid molar ratio of 1:5000 appreciable leakage
could be detected in the absence of lipid mixing. Higher initial
rates of leakage and leakage in the absence of lipid mixing
seem to indicate that the permeabilization process was not a
consequence of leaky fusion induced by the peptide. From
these data we can conclude that partitioning of HIVc into
DOPC/DOPE/CHOL vesicles induced two types of destabili-
zation, rupture of the permeability barrier and membrane
merging.
In order to judge the functional signi¢cance of the mem-
brane perturbations induced by HIVc, and its speci¢city as a
fusogen, we also measured the ability of HIVcÿmut to destabi-
lize vesicles under similar conditions. In the latter sequence
the ¢rst three Trp residues were replaced by Ala, a substitu-
tion known to render a defective gp41 phenotype unable to
mediate both cell^cell fusion and virus entry [11]. Results in
Fig. 2 clearly indicate that HIVcÿmut was also unable to in-
duce signi¢cant lipid mixing even at the highest lipid-to-pep-
tide ratio tested of 1:100. The mutant sequence induced par-
tial release of the aqueous contents of the vesicles but always
below the levels induced by the functional one. The small
leakage caused by HIVcÿmut most likely re£ects the change
in vesicle permeability produced after peptide mass transfer
rather than the e¥ux of aqueous contents through de¢ned
pore-like structures.
The results displayed in Fig. 3 prove that the HIVc peptide
behaved as a true fusogen. The kinetics of membrane mixing
(curves) are shown together with simulations by means of a
mass action kinetic model (dots). The model describes the
fusion process as consisting of two steps, aggregation of
vesicles, which is a second-order process, and the fusion re-
action itself, considered to be a ¢rst-order process. The exper-
imental results and calculated values by the model agreed
fairly well for HIVc-induced fusion of DOPC/DOPE/CHOL
LUV. This procedure yielded directly the fusion rate constants
at di¡erent peptide-to-lipid ratios. Changes in this parameter
are essential to demonstrate the involvement of a putative
fusogen in the fusion reaction itself, as opposed to possible
Fig. 2. Peptide-induced destabilization of DOPC/DOPE/CHOL (mo-
lar ratio, 1:1:1) LUV as detected by leakage (ANTS/DPX assay)
and membrane lipid mixing (RET assay). A: Leakage (dotted lines)
and membrane lipid mixing (continuous lines) detected simultane-
ously as a function of time. HIVc (1) and HIVcÿmut (2) were added
(peptide-to-lipid mol ratio, 1:250) to the vesicles (lipid concentra-
tion, 50 WM) at the time indicated by the arrow. B: Extents of leak-
age (inverted triangles) and membrane lipid mixing (circles) as a
function of peptide-to-lipid molar ratio (after 5 min.). Filled sym-
bols: HIVc ; open symbols: HIVcÿmut. Lipid concentration was 50
WM.
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e¡ects at the level of the preceding aggregation step. Values
displayed in Table 1 further demonstrate that, while the ag-
gregation rate constant remained roughly unchanged, the fu-
sion rate constant increased by almost 20-fold from 0.013 s31
to 0.2 s31 when the peptide-to-lipid ratio increased from 1:500
to 1:50 indicating that HIVc was directly involved in the fu-
sion process. This strongly supports the idea of HIVc being
capable and su⁄cient for destabilizing two interacting mem-
branes.
Finally, structural infrared spectroscopic results shown in
Fig. 4 are consistent with the ability of the HIVc sequence to
fold adopting an K-helix conformation. The amide I band in
deuterated bu¡er (Fig. 4A) shows for HIVc a maximum ap-
pearing at 1644 cm31. The width of the band precludes the
assignment to a single structural component. In the region
where the maximum is found, the presence of unordered
structures has been described (V1643 cm31) together with
absorption by K-helical conformations (1641^1658 cm31)
[27]. An additional shoulder at 1574 cm31 comes from side
chains of Asp residues. By contrast, within the same amide I
region, HIVcÿmut predominantly absorbs at 1625 cm31, a
band related to intermolecular interaction of L-like extended
conformations. The higher frequency shoulder that appears in
the spectrum at V1660 cm31 is of uncertain assignment and
most likely arises from either parallel L-sheets or L-turns [27].
The spectra in Fig. 4B show again a di¡erent conforma-
tional behavior of the sequences also in contact with the
DOPC/DOPE/CHOL LUV. The spectrum corresponding to
HIVc displays within the amide I region a conspicuous band
centered at 1656 cm31 indicative of a preferential K-helical
structure adopted by the peptide fraction bound to vesicles.
Again the main conformation adopted by HIVcÿmut under
comparable conditions seems to be di¡erent from that of
the ‘wild-type’. In fact, the presence of lipid bilayers does
not appear to modify signi¢cantly the conformation of this
peptide. Both spectra in Fig. 4B also display a strong absorp-
tion at V1730 cm31 due to the stretching vibration of phos-
pholipid carbonyl groups. We conclude that the sequence rep-
resenting the non-functional gp41 is defective in its capacity to
fold adopting an K-helical conformation both in bu¡er and in
membranes.
The experimental results in Figs. 1^3 and Table 1, i.e. a
tendency to partition into membrane interfaces with high af-
¢nity, and an ability to destabilize membranes inducing leak-
age and fusion, seem to indicate that HIVc behaves as a mem-
brane-perturbing agent. By comparison HIVcÿmut, a peptide
representing a defective gp41 pre-transmembrane region, was
unable to induce signi¢cant lipid mixing and promoted only
marginal permeabilization of vesicles. Therefore, these results,
together with previous mutational analysis and functional
characterization of the mutants in transfected cells [11,12],
o¡er compelling evidence of a direct involvement of the pre-
transmembrane gp41 sequence in HIV-1 fusion.
Our structural analysis (Fig. 4) also suggests that adoption
of an K-helical conformation by this region might be an im-
Fig. 3. Kinetics of HIVc-induced membrane lipid mixing of DOPC/
DOPE/CHOL (1:1:1) LUV as a function of peptide-to-lipid molar
ratio. Vesicle concentration was 50 WM. Experimental results are
given by solid curves. Closed circles indicate values obtained from
simulation of the results using a mass action kinetic model (see Ma-
terials and Methods).
Table 1














1:50 0.2 8U108 0.001
1:100 0.07 8U108 0.001
1:250 0.035 5U108 0.001
1:500 0.013 5U108 0.001
aLipid concentration was constant at 50 WM. Values derived from
experiments as shown in Fig. 3.
Fig. 4. A: IR spectra of HIVc (wild) and HIVcÿmut (mut) in D2O
bu¡er. B: IR spectra of HIVc (wild) and HIVcÿmut (mut) associated
with DOPC/DOPE/CHOL vesicles. Peptide and vesicles were incu-
bated at a peptide-to-lipid ratio of 1:250, peptide bound to vesicles
was subsequently isolated by £otation in D2O bu¡er as previously
described [16,24].
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portant functional feature of gp41. The possibility that HIVc
in solution might fold partially adopting an K-helical structure
indicates that this sequence might have the ability to oligo-
merize giving rise to assemblies of de¢ned quaternary struc-
ture. This feature in turn might be related to the original
organization existing in the pre-transmembrane region within
the gp41 complex [4,5]. Thus, this sequence might exist as an
integral part of gp41 not necessarily in direct contact with the
membrane. In such a state, formation of oligomers or inter-
actions with hydrophobic pockets in gp41 might reduce the
water accessibility of non-polar surfaces. Nevertheless, our
data con¢rm the intrinsic potential of this sequence to parti-
tion into membrane interfaces. It is tempting to speculate at
this point that expression of such a potential might be under
regulation and evolve only upon fusion activation.
Our results also demonstrate that the membrane-perturbing
action of the gp41 pre-transmembrane sequence in the DOPC/
DOPE/CHOL system is qualitatively similar to that displayed
by the N-terminal fusion peptide [24,25]. Peisajovich et al. [28]
have recently reported that the polar region consecutive to the
fusion peptide might contribute to its fusogenic activity. Thus,
the putative structural organization at the N-terminus of the
fusion-active gp41 consisting of a stretch of highly hydropho-
bic residues inserted into the target membrane, and followed
by a fusogenic membrane surface-associated sequence, might
be mirrored by sequences in the transmembrane region of the
protein ectodomain. In the latter case, insertion through the
hydrophobic transmembrane sequence would occur into the
virion envelope whereas the adjacent fusogenic sequence
would lie associated with the virion membrane interface.
Therefore, it is conceivable that both the N-terminal and
pre-TM region might be involved in the simultaneous distor-
tion of apposed bilayers at the spots where gp41-mediated
fusion is taking place.
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